Wednesday July 18, 2018

Brain mechanism behind depression, an explained research

0
//
53
350 million people are known to suffer depression Pixabay
350 million people are known to suffer depression Pixabay
Republish
Reprint

The findings, published in the journal Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, provide clues as to which regions of the brain could be at the root of symptoms, such as reduced happiness and pleasure, or negative memories, in depression.

Over 5 crore people in India are known to suffer depressive disorders Pixabay
Over 5 crore people in India are known to suffer depressive disorders Pixabay

Findings

  • Brain regions involved in reward and subjective pleasure received less drive (or reduced effective connectivity) in patients, which may contribute to the decreased feeling of happiness in depression.
  • In addition, brain regions involved in punishment and responses when a reward is not received had increased activity, providing evidence for the source of sadness that occurs in the disorder.
  • Memory-related areas of the brain had increased activity and connectivity in people with depression, which the authors suggest may be related to heightened memory processing, possibly of unpleasant memories, in depression.

“These findings are part of a concerted approach to better understand the brain mechanisms related to depression, and thereby to lead to new ways of understanding and treating depression,” said one of the researchers Edmund Rolls, Professor at University of Warwick in England.

86 million people in South-east Asia suffer from depression Pixabay
86 million people in South-east Asia suffer from depression Pixabay

Method

  • For the study, the researchers used a new approach to measure the influence of one brain region on another, referred to as effective connectivity, in depression.
  • The approach goes beyond the limitations of previous brain imaging studies, which show if — but not how — activity of different brain regions is related.
  • The new method allows the effect of one brain region on another to be measured in depression, in order to discover more about which brain systems make causal contributions to depression.
  • The researchers compared 336 people with major depressive disorder to 350 healthy controls. (IANS)

 

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

HIV Drug Is Not Linked to Depression: Study

A new study of a popular HIV drug could ease concerns about its link to depression

0
A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala.
A doctor draws blood from a man to check for HIV/AIDS at a mobile testing unit in Ndeeba, a suburb in Uganda's capital, Kampala. VOA

A new study of a popular HIV drug could ease concerns about its link to depression. Researchers in Uganda found that efavirenz, once feared to lead to depression and suicide, did not cause the expected negative side effects in their patients.

Efavirenz is an affordable, once-a-day pill used around the globe to treat and prevent HIV/AIDS. It’s “the treatment of choice” in most of the world, according to Africa Health Research Institute’s Mark Siedner, “especially [in] countries that depend on global aid to treat HIV.”

But some fear that efavirenz may come with a cost.

Some studies in the United States and Europe found the drug increased patients’ risk of depression or suicide, although other studies did not.

The mixed results prompted many doctors in the United States to prescribe more expensive but potentially safer drugs.

Siedner wanted to take another look at the risk of depression, this time in an African population. From 2005 until 2015, he and a team of Ugandan and U.S. doctors tracked 694 patients who took either efavirenz or another antiretroviral medication. They regularly asked the patients whether they experienced depression or suicidal thoughts.

No difference

Their analysis, published in the Annals of Internal Medicine, showed there was no difference between the two treatments. Siedner told VOA, “In other words, efavirenz was not associated with a risk of depression. If anything, there seems to be a signal that potentially it was associated with a decreased risk. But it wasn’t a strong enough [signal] for us to say that.”

The authors also reported that of the 17 participants who died in the course of the study, not a single death was a suicide.

Siedner has two possible explanations for why their findings differed from those in Western countries. “One potential cause is that every single ethnic group in the world, of course, is different, and different in many different ways — different socially, different environmentally, and in this case they may be different genetically.” His team is looking at whether the genes that control metabolism of the drug have a role to play in this story.

HIV Aids is a deadly disease.
HIV virus is Not Linked To Depression. Flickr

A second explanation could be the effectiveness of the drug. Because efavirenz is so potent, it could be keeping people healthier than they expected, so patients are less likely to report negative emotions.

The study is important, said Anthony Fauci, who heads the National Institute of Allergy and Infectious Diseases, because it pushes back against “the initial observation of suicidal ideation and suicide and depression” as caused by efavirenz. He told VOA, “I think now what you’re seeing is that with these conflicting reports, it’s likely someone will come in [with] the proposal to do a randomized study and take a look. So the story isn’t ended with this paper.”

As more research on the safety of efavirenz is conducted, new and cheaper drugs that might replace it are on the horizon. One of them, dolutegravir, might also pose a risk, however. A study in Botswana found dolutegravir was linked to neural tube defects in embryos, meaning it might not be safe for pregnant women. As always, further research is needed to confirm whether this is a common problem or specific to the population studied in Botswana.

Also read: UNAIDS : World Is At A “Defining Moment” In A Battle Against HIV/AIDS

“I think the whole field right now is in a bit of a holding pattern,” Siedner said when asked about dolutegravir and the future of HIV medication. (VOA)